BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27601021)

  • 1. Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.
    Liakou CG; Mastorakos G; Makris K; Fatouros IG; Avloniti A; Marketos H; Antoniou JD; Galanos A; Dontas I; Rizos D; Tournis S
    Endocrine; 2016 Nov; 54(2):543-551. PubMed ID: 27601021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
    Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
    Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sex steroids on serum sclerostin levels during the menstrual cycle.
    Cidem M; Usta TA; Karacan I; Kucuk SH; Uludag M; Gun K
    Gynecol Obstet Invest; 2013; 75(3):179-84. PubMed ID: 23429230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
    Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
    Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
    Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Anastasilakis AD; Kountouras J; Makras P; Papatheodorou A; Kokkoris P; Sakellariou GT; Terpos E
    J Bone Miner Metab; 2016 Jul; 34(4):447-56. PubMed ID: 26056025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
    Peng J; Dong Z; Hui Z; Aifei W; Lianfu D; Youjia X
    BMC Musculoskelet Disord; 2021 May; 22(1):480. PubMed ID: 34034718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women.
    Gass ML; Kagan R; Kohles JD; Martens MG
    Menopause; 2008; 15(4 Pt 1):667-75. PubMed ID: 18327152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Rossini M; Adami S
    J Clin Endocrinol Metab; 2011 May; 96(5):1555-9. PubMed ID: 21367927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preeclampsia - a risk factor for osteoporosis? Analysis of maternal Sclerostin levels and markers of bone turnover in patients with pre-eclampsia.
    Wild J; Pateisky P; Küssel L; Huf W; Ott J; Haslinger P; Knöfler M; Zeisler H
    Hypertens Pregnancy; 2014 Aug; 33(3):333-40. PubMed ID: 24568269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
    Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
    J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women.
    Costa AG; Walker MD; Zhang CA; Cremers S; Dworakowski E; McMahon DJ; Liu G; Bilezikian JP
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4736-43. PubMed ID: 24037879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.